ElexoPharm takes €1.5M upfront in collaboration with Merck

Licensing | Collaboration

ElexoPharm GmbH has announced a collaboration and exclusive worldwide license agreement with Merck & Co., Inc. to develop and commercialise novel candidates targeting aldosterone synthase, for the potential treatment of cardiovascular disease.

Under the terms of the agreement, Merck will pay ElexoPharm an upfront payment of €1.5 million. In addition, ElexoPharm is eligible to receive up to an additional €32.3 million on specific development, regulatory and commercial milestones, plus royalties on net sales of any products resulting from the collaboration. Merck is responsible for development, regulatory filings, manufacturing and commercialisation.

“This agreement marks a major milestone in ElexoPharm’s relatively recent company history,” said Axel Koch, Managing Director of ElexoPharm,

ElexoPharm, of Saarbruecken, was founded as a spin-out from the Department of Pharmaceutical and Medicinal Chemistry of Saarland University. The company is focused on preclinical medicinal chemistry research.